Integra Lifesciences Holdings (IART) Change in Receivables (2009 - 2026)

Integra Lifesciences Holdings has disclosed Change in Receivables across 18 years of filings, most recently posting $3.0 million for Q2 2026.

• In Q2 2026, Change in Receivables fell 89.14% year-over-year to $3.0 million; the TTM figure through Jun 2026 stood at -$16.7 million (down 280.04% YoY), while the FY2025 annual figure was $485000.0, up 106.56% from the prior year.
• Change in Receivables came in at $3.0 million for Q2 2026 at Integra Lifesciences Holdings, up from -$13.6 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $31.5 million in Q4 2024 to a low of -$28.8 million in Q3 2024.
• Average Change in Receivables over 5 years is $655277.8, with a median of $3.1 million recorded in 2022.
• The largest YoY upside for Change in Receivables was 6784.68% in 2024 against a maximum downside of 12734.82% in 2024.
• Over 5 years, Change in Receivables stood at $10.0 million in 2022, then plunged by 95.45% to $457000.0 in 2023, then jumped by 6784.68% to $31.5 million in 2024, then slumped by 47.71% to $16.5 million in 2025, then sank by 81.52% to $3.0 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $3.0 million in Q2 2026, -$13.6 million in Q1 2026, and $16.5 million in Q4 2025.